Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of Single-dose CRB4101 in Healthy Adults
NCT05641181Phase 1Unknown
- Sponsor
- China Resources Pharmaceutical Group
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CRB4101 in venous thromboembolism (VTE) (7 arms), sponsored by China Resources Pharmaceutical Group. Primary endpoint: Adverse Events at 20 days. Status: unknown.
02
Drugs
CRB4101
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05641181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641181.